Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects.
Chimalakonda Anjaneya, Singhal Shalabh, Darbenzio Raymond, +8 more·Clinical pharmacology in drug development
Deucravacitinib is a novel, oral, selective inhibitor of the intracellular signaling kinase tyrosine kinase 2. This phase 1, randomized, partially double-blind, 4-period crossover study in healthy adults was conducted to determine whether deucravacitinib 12 mg (therapeutic dose) or 36 mg (supratherapeutic dose) had a c…